

Our Ref: 428/2023
September 2023

Re: Your request made under the Freedom of Information Act 2000

It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] - 15
- Adalimumab [Humira] - 30
- Adalimumab Biosimilars - 446
- Apremilast [Otezla] - 1
- Baricitinib [Olumiant] - 35
- Bimekizumab [Bimzelx] - 0
- Certolizumab [Cimzia] - 21
- Etanercept [Enbrel] - 30
- Etanercept Biosimilars - 189
- Filgotinib [Jyseleca] - 53
- Golimumab [Simponi] - 76
- Guselkumab [Tremfya] - 4
- Infliximab [Remicade] - 7
- Infliximab Biosimilars - 17
- Ixekizumab [Taltz] - 8
- Risankizumab [Skyrizi] - 0
- Rituximab [MabThera] - 0
- Rituximab Biosimilars - 29
- Sarilumab [Kevzara] - 6
- Secukinumab [Cosentyx] - 50
- Tocilizumab [Ro Actemra] - 32
- Tofacitinib [Xeljanz] - 5
- Upadacitinib [Rinvoq] - 27
- Ustekinumab [Stelara] - 4